<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902525</url>
  </required_header>
  <id_info>
    <org_study_id>ZETAL07</org_study_id>
    <nct_id>NCT00902525</nct_id>
  </id_info>
  <brief_title>Zevalin Twice in Aggressive Non-Hodgkin Lymphoma</brief_title>
  <official_title>Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite of the availability of treatment for this disease, this study is justified because no
      known therapies are really curative and it is necessary to look for new treatment options to
      improve the clinical outcome and prognosis of relapsed aggressive lymphoma. This study is
      designed for patients not eligible for high-dose chemotherapy and autologous stem cells
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to evaluate the efficacy and safety of two sequential doses
      of 90Y-Ibritumomab Tiuxetan administered after salvage chemotherapy in patients with
      relapsed/refractory aggressive lymphoma non-eligible for HDC and ASCT.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    After enrolling 25 patients an interim analysis was done.The study was discontinued in the
    absence of the minimum number of 6 patients free of events
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An interim analysis on all the available data after the enrolment of the 15th patient (completion of the 1st stage) will be conducted, both for safety and efficacy.</measure>
    <time_frame>after the enrolment of the 15th patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>after the interim analysis, the writing committee of the study will evaluate to increase the second dose of Zevalin to 0.3 mCi/Kg. The same procedure will be applied to decide if the trial must be stopped after the enrolment of the 23rd patient.</measure>
    <time_frame>after the enrolment of the 23rd patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>90Y-Ibritumomab Tiuxetan double dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y-Ibritumomab Tiuxetan</intervention_name>
    <description>All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan</description>
    <arm_group_label>90Y-Ibritumomab Tiuxetan double dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75

          2. Diagnosis of CD20+ B-diffuse large cell de novo or transformed or follicular lymphoma
             grade IIIb

          3. Stage II, III, IV according to Ann Arbor criteria

          4. Chemoresistant disease after first line treatment (CHOP-like + Rituximab) or relapsed
             patients after one or two lines of chemotherapy not-eligible for high dose
             chemotherapy and autologous stem cell transplantation

          5. Performance status 0-2 according to WHO criteria

          6. HIV negativity

          7. Normal liver, lung and kidney function: conjugated bilirubin up to 2 x ULN, alkaline
             phosphatase and transaminases up to 2 x ULN, creatinine clearances ≥45 ml/min

          8. Neutrophils count ³ 1.5 x 109/l, Haemoglobin ³ 9 g/dl, Platelets ³ 150 x 109/l and
             bone marrow involvement &lt; 25% before first Zevalin infusion.

          9. Neutrophils count ³ 1.5 x 109/l, Haemoglobin ³ 9 g/dl, Platelets ³ 100 x 109/l before
             second Zevalin infusion

         10. Use of effective contraception for the entire treatment period in patients sexually
             active

         11. Negative pregnancy test in child bearing potential women

         12. Life expectancy &gt; 6 months

         13. Written informed consent

        Exclusion Criteria:

          1. More than two lines of prior chemotherapy before study entry

          2. Prior high dose chemotherapy and autologous stem cell transplantation

          3. HIV positivity

          4. HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with
             HBV-DNA negative

          5. HCV positivity with the exception of patients with no signs of active chronic
             hepatitis histologically confirmed

          6. History of clinically relevant liver or renal insufficiency; significant cardiac,
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,
             hematologic, psychiatric, or metabolic disturbances

          7. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable
             dose for at least 3 months before first dose of study drug

          8. Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure
             (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina,
             clinically significant pericardial disease, or cardiac amyloidosis

          9. Pregnant or breastfeeding

         10. CNS lymphoma involvement.

         11. History of malignant carcinoma within the last 3 years other than squamous cell and
             basal cell carcinoma.

         12. Cardiac failure with VEF &lt; 40%

         13. Clinical evidence of not controlled infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Botto, MD</last_name>
    <role>Study Director</role>
    <affiliation>SCDO Ematologia AOU San Giovanni Battista Torino</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Umberto Vitolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCDO Ematologia 2 AOU San Giovanni Battista Torino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale SS Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia e Oncologia Medica L. Seragnoli Policlinco S. Orsola</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Centrale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Cardinale Panico</name>
      <address>
        <city>Tricase</city>
        <state>LE</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Niguarda Cà Granda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncoematologia IRCC</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Istituto Nazionale Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia Ospedale Maggiore Università Avogadro</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncoematologia Azienda Ospedalier S. Maria</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDO Ematologia 2 AOU San Giovanni Battista</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2009</study_first_posted>
  <last_update_submitted>December 28, 2012</last_update_submitted>
  <last_update_submitted_qc>December 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>two sequential doses of 90Y-Ibritumomab Tiuxetan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

